- Works count
- 1,103
- Citation count
- 72,492
- H-index
- 116
- i10-index
- 447
Research interests
Publications
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.009
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00772-9
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO Open · 2023 · https://doi.org/10.1016/j.esmoop.2023.101567
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.506
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.030
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30791-5
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
JNCI Journal of the National Cancer Institute · 2017 · https://doi.org/10.1093/jnci/djx015
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv295
A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs
Journal of Gastrointestinal Cancer · 2015 · https://doi.org/10.1007/s12029-015-9724-1
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Science · 2015 · https://doi.org/10.1126/science.aad0779
Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-15-0526
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70212-8
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt523
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Endocrine Related Cancer · 2013 · https://doi.org/10.1530/erc-13-0027
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Journal · 2012
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1011923
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.27.6055
Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.21.6796
Immunogenic death of colon cancer cells treated with oxaliplatin
Oncogene · 2009 · 10.1038/onc.2009.356
Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.19.9273
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.12.5906
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Cancer Research · 2006 · https://doi.org/10.1158/0008-5472.can-06-0191
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2006.06.7629
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.06.023
A phase II study
European Journal of Cancer · 2000 · https://doi.org/10.1016/s0959-8049(00)00072-1
Current projects
No projects listed.